Intracellular Signaling Responses Induced by Radiation within an In Vitro Bone Metastasis Model after Pre-Treatment with an Estrone Analogue
Open Access
Abstract
2-Ethyl-3-O-sulfamoyl-estra-1,3,5(10)16-tetraene (ESE-16) is an in silico-designed estradiol analogue which has improved the parent compound’s efficacy in anti-cancer studies. In this proof-of-concept study, the potential radiosensitizing effects of ESE-16 were investigated in an in vitro deconstructed bone metastasis model. Prostate (DU 145) and breast (MDA-MB-231) tumor cells, osteoblastic (MC3T3-E1) and osteoclastic (RAW 264.7) bone cells and human umbilical vein endothelial cells (HUVECs) were representative components of such a lesion. Cells were exposed to a low-dose ESE-16 for 24 hours prior to radiation at non-lethal doses to determine early signaling and molecular responses of this combination treatment. Tartrate-resistant acid phosphatase activity and actin ring formation were investigated in osteoclasts, while cell cycle progression, reactive oxygen species generation and angiogenic protein expression were investigated in HUVECs. Increased cytotoxicity was evident in tumor and endothelial cells while bone cells appeared to be spared. Increased mitotic indices were calculated, and evidence of increased deoxyribonucleic acid damage with retarded repair, together with reduced metastatic signaling was observed in tumor cells. RAW 264.7 macrophages retained their ability to differentiate into osteoclasts. Anti-angiogenic effects were observed in HUVECs, and expression of hypoxia-inducible factor 1-α was decreased. Through preferentially inducing tumor cell death and potentially inhibiting neovascularization whilst preserving bone physiology, this low-dose combination regimen warrants further investigation for its promising therapeutic application in bone metastases management, with the additional potential of limited treatment side effects.Keywords
Funding Information
- Cancer Association of South Africa (AOV741, AOW228)
- National Research Foundation (NRF 105992, 90523, 85818)
- Struwig-Germeshuysen Kankernavorsingstrust (AON074)
- The School of Medicine Research Committee of the University of Pretoria (RESCOM) (AOR984)
This publication has 80 references indexed in Scilit:
- RANKL/RANK/MMP-1 Molecular Triad Contributes to the Metastatic Phenotype of Breast and Prostate Cancer Cells In VitroPLOS ONE, 2013
- End-binding proteins sensitize microtubules to the action of microtubule-targeting agentsProceedings of the National Academy of Sciences, 2013
- Role of tartrate-resistant acid phosphatase (TRAP) in long bone developmentMechanisms of Development, 2012
- The evolution of the cytoskeletonJournal of Cell Biology, 2011
- Drugs that target dynamic microtubules: A new molecular perspectiveMedicinal Research Reviews, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic BiomarkersClinical Cancer Research, 2010
- The Yin and Yang of bone morphogenetic proteins in cancerCytokine & Growth Factor Reviews, 2010
- CXCR4 and Matrix Metalloproteinase-1 Are Elevated in Breast Carcinoma–Associated Fibroblasts and in Normal Mammary Fibroblasts Exposed to Factors Secreted by Breast Cancer CellsMolecular Cancer Research, 2009
- G2E3 is a nucleo-cytoplasmic shuttling protein with DNA damage responsive localizationExperimental Cell Research, 2007